Lawsuits over baby powder are no longer the only worry for Johnson & Johnson investors as pharmaceutical sales come under price and sales pressure.
View full coverage on Google Newsfrom Top stories - Google News https://on.wsj.com/2R6feCb
Subscribe to:
Post Comments (Atom)
-
By BENJAMIN MUELLER from NYT New York https://ift.tt/2lLfnOi
-
By LAURA LIPPMAN from NYT Opinion https://ift.tt/2KCQH8N
No comments:
Post a Comment